ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

larazotide acetate

Also written as “Larazotide Acetate”, “Larazotide” and “Larazotide acetate”.

Its studies are mostly in Celiac Disease · Fabry Disease, led by 3 companies.

Drug pageLarazotide acetate: every studyAll 13 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Jun 14, 201812 company-led studies, 1 open or runningNext primary completion: Aug 2028 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
9 Meters Biopharmaits history only80 open or runningphase 3since Jun 14, 2018Aug 8, 2006none ahead
BioMarin Pharmaceutical30 open or runningphase 1since Nov 10, 2011Nov 10, 2011none ahead
Interlude Biopharmaits history only11 open or runningphase 3since Nov 10, 2026Nov 10, 2026Aug 2028phase 3 · NCT07944625

Also a collaborator on its studies: Teva Pharmaceutical Industries.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of BioMarin Pharmaceutical only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 10, 2011First study: phase 1 study in Fabry DiseaseFirst studyNCT01853852 · 14 enrolled · Australia
  2. Nov 8, 20122 phase 1 studies in Fabry DiseaseNCT01730482, NCT01730469

TargetBeta

“Neuronal acetylcholine receptor; alpha3/beta4 partial agonist”ChEMBL 37, by rule

Studies

All 3 BioMarin Pharmaceutical leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT01730482Fabry Disease1CompletedSep 20116
NCT01730469Fabry Disease · United States1CompletedApr 201232
NCT01853852Fabry Disease · Australia1CompletedDec 201114

How it is read

Names in the registry

  • “larazotide acetate”, 5 entries
  • “Larazotide Acetate”, 2 entries
  • “Larazotide”, 1 entry
  • “Larazotide acetate”, 1 entry
  • “AT1001 150 mg”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.